Saturday, June 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

A guide to help you keep up with the omicron subvariants

by Medical Finance
in Coronavirus
Surveying communities may be a useful tool for predicting COVID-19 case trajectories
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

Two years into the coronavirus pandemic, Americans can be forgiven if they’ve lost track of the latest variants circulating nationally and around the world. We’ve heard of the alpha, beta, gamma, delta, and omicron variants, but a new Greek-letter variant hasn’t come onto the scene in almost half a year.

Instead, a seemingly endless stream of “subvariants” of omicron, the most recent Greek-letter variant, has emerged in the past few months.

How different are these subvariants from one another? Can infection by one subvariant protect someone from infection by another subvariant? And how well are the existing coronavirus vaccines — which were developed before omicron’s emergence — doing against the subvariants?

We asked medical and epidemiological experts these and other questions. Here’s a rundown.

Q: What are the subvariants? How much do they differ from one another?

The omicron subvariants seem like an alphabet soup of letters and numbers. The original omicron variant was called B.1.1.529. The initial omicron variant begat such subvariants as BA.1; BA.1.1; BA.2; BA.2.12.1; BA.3; and the most recent, BA.4 and BA.5.

“They all differ from each other by having different mutations in the spike protein,” which is the part of the virus that penetrates host cells and causes infection, said Dr. Monica Gandhi, a professor of medicine at the University of California-San Francisco.

The minor-to-modest mutations in these subvariants can make them marginally more transmissible from person to person. Generally, the higher the number following “BA” in the subvariant’s name, the more transmissible that subvariant is. For instance, BA.2 is thought to be about 30% to 60% more transmissible than previous subvariants.

These mutations have enabled subvariants to spread widely, only to be overtaken by a slightly more transmissible subvariant within a few weeks. Then the process repeats.

In the United States, for instance, BA.1.1 was dominant in late January, having overtaken the initial variant, B.1.1.529. But by mid-March, BA.1.1 began losing ground to BA.2, which became dominant by early April. By late April, another subvariant — BA.2.12.1 — was gaining steam, accounting for almost 29% of infections, according to data from the Centers for Disease Control and Prevention. (The delta wave of late 2021 has been a non-factor during this time frame.)

Q: What about the severity of illness?

Fortunately, the illnesses caused by omicron have typically been less severe than those caused by previous variants — a pattern that seems to hold for all the subvariants studied so far. One analysis from Denmark showed that BA.2 doesn’t cause more hospitalizations than the BA.1 subvariant, Gandhi said.

Even the most recent subvariants that have been discovered, BA.4 and BA.5, show “no evidence to suggest that it is more worrisome than the original omicron, other than a potentially slight increase in transmissibility,” said Brooke Nichols, an infectious-disease mathematical modeler at Boston University.

Dennis Cunningham, the system medical director of infection control and prevention at Henry Ford Health in Detroit, told NBC News that the symptoms from the omicron subvariants “have been pretty consistent. There’s less incidence of people losing their sense of taste and smell. In a lot of ways, it’s a bad cold, a lot of respiratory symptoms, stuffy nose, coughing, body aches, and fatigue.”

Q: If you get infected by one subvariant, will you be protected against others?

So far, in all variants to date, the ability of the virus to evade existing immune protection “is only partial, much like it is for the seasonal flu,” said Colin Russell, a professor of applied evolutionary biology at the University of Amsterdam’s medical center.

While some people who had BA.1 have also gotten BA.2, the initial research suggests that infection with BA. 1 “provides strong protection against reinfection with BA.2,” the World Health Organization has said.

“This may explain why our BA.2 surge in the U.S. was not that large as the very large BA.1 surge over the winter,” Gandhi said.

The level of protection can vary depending on how sick you were, with mild cases boosting immunity for perhaps a month or two and recovery from a severe illness granting up to a year.

Q: How do existing covid-19 vaccines stack up against these subvariants?

Although the current vaccines and boosters aren’t quite as successful in protecting against omicron as they are against earlier variants, they will generally protect people from severe disease if they are infected by one of the new subvariants.

“We’re steady as she goes with the vaccines we’re using,” said Dr. William Schaffner, a professor of preventive medicine and health policy at Vanderbilt University. “I have not seen a single study from the field that shows a substantial distinction between the vaccine responses to omicron subvariants.”

The vaccines generate cells known as “memory B cells” and have been shown to recognize different variants as they emerge, Gandhi said. The vaccines also trigger the production of T cells, which protect against severe disease, she said.

“While B cells serve as memory banks to produce antibodies when needed, T cells amplify the body’s response to a virus and help recruit cells to attack the pathogen directly,” Gandhi said.

The end result is that a breakthrough infection for a vaccinated individual “should remain mild with the subvariants,” she said.

The wide spread in the U.S. of a relatively mild strain of the virus likely paid dividends by providing many Americans with some immunity, whether or not they had been vaccinated. Research shows that people who had been vaccinated and then were infected had even greater protection than people who had been vaccinated and not gotten covid.

“This family of omicron could indeed offer a bright side” in the course of the pandemic, Schaffner said.

Looking ahead, vaccine manufacturers are beginning to design vaccines that specifically target omicron, and some would combine a coronavirus vaccine with a seasonal influenza vaccine in one shot. But these vaccines are in their early stages, and Schaffner said he suspects they won’t be ready and approved by this fall’s flu vaccination season.

Whether such new vaccines represent the next step in the fight against covid will be up to the FDA and the CDC.

Q: Are any entirely new variants on the horizon?

Experts agreed that the only newcomers in recent weeks have been incremental subvariants — certainly nothing that seems as game changing as delta or omicron were when they first appeared.

“There’s nothing we know of that’s lurking yet, and the surveillance is pretty darn aggressive,” Schaffner said.

There are estimates that more than 60% of the world’s population has been exposed to omicron and over 65% of the world’s population has received at least one dose of the vaccine, Gandhi said, “so I am keeping my fingers crossed the development of new variants will slow with this degree of population immunity.”

Gandhi acknowledged some surprise at how quiet the horizon is right now, but she sees it as a positive development.

“We have now gone five months since hearing about a new variant, which I hope is reflective of increasing immunity in the world’s population,” she said.




Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents. Image Credit: Irina Shatilova/Shutterstock

Declining effectiveness of the BNT162b2 vaccine in adolescents infected with COVID-19

by Medical Finance
June 25, 2022
0

The coronavirus disease 2019 (COVID-19) pandemic has been caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus....

Study: SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation. Image Credit: CROCOTHERY/Shutterstock

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

by Medical Finance
June 25, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that produced the coronavirus disease 2019 (COVID-19) pandemic has resulted in...

Study: SARS-CoV-2 spreads through cell-to-cell transmission. Image Credit: MIA Studio/Shutterstock

SARS-CoV-2 shown to spread through cell-to-cell transmission

by Medical Finance
June 25, 2022
0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel beta-coronavirus that is closely related to severe acute respiratory syndrome...

Study: Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021. Image Credit: Ralf Liebhold/Shutterstock

Association of vaccination status with Long COVID symptoms

by Medical Finance
June 25, 2022
0

An emerging and complex health problem that remains poorly characterized and understood is long coronavirus disease 2019 (Long COVID)....

Study: A within-host model of SARS-CoV-2 infection. Image Credit: Kateryna Kon/Shutterstock

Within-host model for the description of SARS-CoV-2 viral dynamics in the upper respiratory tract

by Medical Finance
June 25, 2022
0

A team of UK-based scientists has recently developed a within-host model to determine the dynamics of severe acute respiratory syndrome...

Study: Emerging Therapies for COVID-19: the value of information from more clinical trials. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

by Medical Finance
June 25, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers quantified the cost-effective health benefits of pursuing further research...

Next Post
Study: Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Image Credit: NIKCOA / Shutterstock.com

A dangerous or beneficial plant?

Tissue sample stained using multiple fluorescently labeled antibodies - image generated by Carl Dupont

Going Beyond a Single Color

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Chromosome X microscope. 3d illustration. Anatomy Insider 6d227ed624514887a5747f8229b16cad 620x480
    Potential new diagnostic marker predicts successful, efficient development of mammalian egg cells
  • A doctor makes a vaccination to a child Yuganov Konstantin cdbf1b05417f45e89b8268af4858e1c9 620x480
    Anti-vaccine ideology gains ground as lawmakers seek to erode rules for kids’ shots
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply